Reading the STEP-HFpEF Follow-Up: Semaglutide in Heart Failure
STEP-HFpEF established semaglutide as beneficial in adults with obesity and heart failure with preserved ejection fraction, a population historically without many effective pharmacologic options. Follow-up data has extended the picture. Here's the current evidence base.
Why HFpEF Matters
Heart failure with preserved ejection fraction (HFpEF) has historically been the harder-to-treat heart failure phenotype. Standard heart failure medications developed for reduced-ejection-fraction disease have often shown minimal or no benefit in HFpEF trials. Effective therapies for this population have been limited.
Obesity is a common contributor to HFpEF, and weight loss has long been recognized as beneficial. The question STEP-HFpEF addressed: whether pharmacologic weight loss with semaglutide translates specifically to improved heart failure outcomes.
The Primary Findings
STEP-HFpEF's primary readout showed improvement in heart failure symptom scores (Kansas City Cardiomyopathy Questionnaire, KCCQ) and 6-minute walk distance in patients on semaglutide compared to placebo. Weight loss was substantial, as expected. NT-proBNP levels (a marker of heart failure severity) improved in the semaglutide arm.
Follow-up analyses have maintained these signals, with continued benefit through longer observation windows. Some analyses have explored subgroups — patients with diabetes vs without, patients with more severe HFpEF vs milder — and generally shown consistent benefit across strata.
Found Health
Brand-name GLP-1 access with coaching layer.
- Brand-name focus
- Coaching + accountability
- Insurance-coordinated
Telos Rx
Compounded tirzepatide via direct pharmacy.
- Compounded tirzepatide
- Direct-link intake
- Verify pricing
What the Trial Didn't Establish
STEP-HFpEF was powered for symptom and functional endpoints, not hard cardiovascular outcomes. Whether semaglutide reduces heart failure hospitalizations or CV death specifically in HFpEF requires larger outcome trials with longer follow-up. Some of that work is ongoing.
The trial also enrolled adults with obesity — not HFpEF patients with normal weight. Whether GLP-1 therapy would benefit lean HFpEF patients is unclear and not addressed by these data.
Oak Weight Loss
Telehealth program with compounded GLP-1 access.
- Compounded GLP-1
- Standard intake
- Membership pricing
How Guidelines Have Responded
Heart failure guidelines have incorporated the HFpEF data as evidence supporting semaglutide use in obese patients with the diagnosis. The recommendation strength varies by guideline body but the direction is consistent: this is an indication that has moved from theoretical to evidence-supported.
Sesame Care
Marketplace for brand-name FDA-approved GLP-1 only.
- Brand-name only
- Direct consult marketplace
- Cash-pay clarity
The Practical Access Question
For patients with obesity and HFpEF, semaglutide access under this indication has become somewhat easier than access under obesity alone. Insurance coverage decisions that would deny obesity-only claims sometimes approve based on the HFpEF indication. Documentation of the diagnosis (echocardiogram with preserved ejection fraction, clinical symptoms) helps establish eligibility.
MadeMed
Independent compounder — sema, tirz, and oral formats.
- Compounded sema/tirz
- Oral tirz option
- Direct pharmacy fulfillment
SHED
Note: SHED's price jumps to $399/mo at 7.5mg+.
- Lower entry pricing
- Price jump at 7.5mg+
- Compounded sema + tirz
Where to Start
SkinnyRx
Reactivated program with oral GLP-1 positioning.
- Oral GLP-1 pathway
- Compounded semaglutide options
- Verify at checkout
Liv Body
Higher-CPA compounded GLP-1 program.
- Compounded GLP-1 fulfillment
- Higher-priced tier
- Verify current pricing
SHED
Note: SHED's price jumps to $399/mo at 7.5mg+.
- Lower entry pricing
- Price jump at 7.5mg+
- Compounded sema + tirz